Yashoda Hospital | Clinical Research Department

Research site

(Unclaimed)

Location

Raj Bhavan Road, Somajiguda, Hyderabad, Telangana, India

Site insights

Top conditions

Top treatments

Dexamethasone

Carfilzomib

Hydroxyurea

Lyrica

Methylprednisolone

Cytarabine

Paclitaxel

Azacitidine

Dacomitinib

Atezolizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 21 total trials

A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with end...

Enrolling

Early Breast Cancer

Drug: Endocrine Therapy of Physician's Choice

Drug: Abemaciclib

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer (EMBER-3)

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy, and how well imlunestrant with abemaci...

Active, not recruiting

Neoplasm Metastasis

Breast Neoplasms

Drug: Imlunestrant

Drug: Abemaciclib

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexameth...

Enrolling

Relapsed or Refractory Multiple Myeloma

Drug: Mezigdomide

Drug: Dexamethasone

A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke (OCEANIC-STROKE)

Researchers are looking for a better way to prevent an ischemic stroke which occurs when a blood clot travelled to the brain in people who within the...

Enrolling

High-risk Transient Ischemic Attack

Acute Non-cardioembolic Ischemic Stroke

Drug: Asundexian (BAY2433334)

Drug: Placebo

Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 (REGAL)

To assess the safety and efficacy of galinpepimut-S (GPS) compared with investigator's choice of best available therapy (BAT) on overall survival (OS...

Active, not recruiting

Acute Myeloid Leukemia

Other: Observation

Other: Montanide

Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

This is a study to explore the effect of oral ozanimod as an induction treatment for participants with moderately to severely active Crohn's Disease.

Active, not recruiting

Crohn Disease

Other: Placebo

Drug: Ozanimod

Research Study Investigating How Well NDec Works in People With Sickle Cell Disease (ASCENT1)

This study examines how well a new, potential medicine called NDec works and is tolerated in people with sickle cell disease. NDec is a combination o...

Enrolling

Sickle Cell Disease

Drug: HU - Hydroxyurea

Drug: Placebo